

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUA MEDICINE

華領醫藥

(Incorporated in the Cayman Islands with limited liability)

(stock code: 2552)

**SUPPLEMENTAL ANNOUNCEMENT
CONTINUING CONNECTED TRANSACTION
SALES AND DISTRIBUTION FRAMEWORK AGREEMENT**

Reference is made to the announcement of the Company dated April 10, 2023 (the “**Announcement**”) in relation to the Sales and Distribution Framework Agreement with 111, Inc. Unless otherwise defined, all capitalized terms used herein shall have the same meanings as defined in the Announcement.

The Company wishes to provide the following additional information in relation to the continuing connected transaction contemplated under the Sales and Distribution Framework Agreement.

INTERNAL CONTROLS FOR THE CONTINUING CONNECTED TRANSACTION

As disclosed in the Announcement, the Company will adopt adequate internal control measures to comply with the Listing Rules requirements with respect to the supervision and monitoring of the annual cap of the transaction contemplated under the Sales and Distribution Framework Agreement. In particular, the Company’s pharmaceutical commercialization team will coordinate with the Company’s distributors and report its monthly transactions and projections to the legal department, financial management department and senior management of the Group, where the breakdowns of the sales amount to each distributor and total sales amount will be made available and the senior management will review the figures generated from connected persons (the list of which shall be reviewed and updated by the legal department from time to time). This measure has been implemented for the April 2023 and year-to-date results, and each subsequent monthly reporting will be conducted within seven business days after the end of each month. The financial management department and the legal team will also review the distribution agreements signed and to be signed with other distributors to ensure that the pricing terms in the Sales and Distribution Framework Agreement are no more favourable than those offered to other independent third parties.

In addition, as consistent with the Company's current internal control policies, the underlying transaction agreements of the Sales and Distribution Framework Agreement are to be executed by the vice president of pharmaceutical commercialization team of the Company. Prior to execution of such underlying transaction agreements by the vice president of pharmaceutical commercialization team, the Group also requires electronic approval by each of the aforementioned departments and the chief executive officer of the Company, through the Company's internal electronic file and approval program, and before such approval each department will confirm that the underlying transaction agreements are compliant with the pricing policy and the terms of the Sales and Distribution Framework Agreement.

In order to ensure that the internal control procedures will be adhered to, the Company has reviewed its internal control framework to ensure that it clearly outlines the internal control procedures that the Company has implemented for managing risks and maintaining compliance. The Company will regularly conduct risk assessments to identify potential areas of compliance weakness and to develop strategies to mitigate those risks. Further, in order to ensure that there is a strong culture of accountability and effective reporting system within the Company, (i) the employees and the senior management will be provided with regular trainings; (ii) the Company plans to appoint a personnel to oversee the implementation of internal control procedures by the end of June 2023; and (iii) the independent non-executive Directors will conduct an annual review on the transactions under the Sales and Distribution Framework Agreement in accordance with the Listing Rules. The trainings will be provided to senior management of the Group, as well as employees in the pharmaceutical commercialization team, legal department and financial management department and will include topics such as internal reporting procedures, connected transactions and discloseable transactions, corporate governance code etc. The Company will provide trainings on a yearly basis, at a minimum frequency of once per year, and such training will be provided by knowledgeable and qualified internal personnel, and/or external counsel or advisers as the Board deems appropriate.

By order of the Board

Hua Medicine

Dr. Li Chen

Chief Executive Officer and Executive Director

Hong Kong, May 11, 2023

As at the date of this announcement, the Board of Directors comprises Dr. Li Chen and Mr. George Chien Cheng Lin as executive Directors; Mr. Robert Taylor Nelsen and Ms. Wei Zhao as non-executive Directors; and Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung as independent non-executive Directors.